Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 05, 2020 08:30 ET | Source: Albireo Pharma, Inc.

Albireo Recognizes PFIC Awareness Day 2020

BOSTON, Oct. 05, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, joins the PFIC Advocacy...
October 02, 2020 16:30 ET | Source: Albireo Pharma, Inc.

Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Oct. 02, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced the...
September 09, 2020 21:16 ET | Source: Albireo Pharma, Inc.

Albireo Prices Public Offering of 4,000,000 Shares of Common Stock

BOSTON, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today the...
September 08, 2020 16:01 ET | Source: Albireo Pharma, Inc.

Albireo Announces Proposed Public Offering of 3,000,000 Shares of Common Stock

BOSTON, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today that it...
September 08, 2020 06:30 ET | Source: Albireo Pharma, Inc.

Albireo Phase 3 Trial Meets Both Primary Endpoints for Odevixibat in PFIC

-Highly statistically significant reductions in both pruritus and serum bile acids- -Well tolerated with very low incidence of diarrhea- -Similar efficacy in children with PFIC1 or PFIC2- -Pivotal...
September 07, 2020 16:36 ET | Source: Albireo Pharma, Inc.

Albireo to Announce Topline Results from PEDFIC 1 Phase 3 Trial of Odevixibat on September 8, 2020

BOSTON, Sept. 07, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that...
August 18, 2020 16:40 ET | Source: Albireo Pharma, Inc.

Albireo Reports Topline Results from Phase 2 Trial of Elobixibat in NAFLD/NASH

‒ Achieved primary endpoint ‒‒ Unremarkable results in key NASH measures ‒‒ Company discontinuing further development ‒ BOSTON, Aug. 18, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq:...
August 06, 2020 07:30 ET | Source: Albireo Pharma, Inc.

Albireo Reports Q2 2020 Financial Results and Provides Business Update

— Completed last patient visits in Phase 3 PFIC and Phase 2 NASH Trials —— Enrolled first biliary atresia patients in second odevixibat pivotal study —— Completed two financing transactions to secure...
July 30, 2020 16:01 ET | Source: Albireo Pharma, Inc.

Albireo to Present at the William Blair Biotech Focus Conference 2020

BOSTON, July 30, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that Ron...
July 30, 2020 08:00 ET | Source: Albireo Pharma, Inc.

Albireo to Report Q2 2020 Financial Results on August 6

— Conference call and webcast to be held at 10:00 a.m. ET — BOSTON, July 30, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company...